Mary Brown
Acute Care · Watkinsville, GANPI 1083178321
Payments from drug & device makers
Across 69 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$214
- Bayer$161
- Novartis$149
- AstraZeneca$113
- Amgen$112
- GSK$65
- plus $515 from 15 others
What the payments were for
- Food & beverage$1,28096%
- Education$484%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 13 | $214 |
| Bayer | 8 | $161 |
| Novartis | 7 | $149 |
| AstraZeneca | 6 | $113 |
| Amgen | 5 | $112 |
| GSK | 4 | $65 |
| Ardelyx, Inc. | 3 | $60 |
| Calliditas Therapeutics US Inc. | 2 | $50 |
| Edwards Lifesciences | 2 | $50 |
| Mallinckrodt Hospital Products Inc. | 2 | $50 |
| Aurinia Pharma U.S., Inc. | 3 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Akebia Therapeutics Inc | 2 | $37 |
| Sanofi | 2 | $34 |
| Fresenius USA Marketing, Inc. | 2 | $31 |
| OPKO Pharmaceuticals, LLC | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $16 |
How this compares
$1,328 in reported general payments places this provider in the 75th percentile of 679 acute care providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 36 | $32,386 |
| Calcitriol | 101 | $1,220 |
| Valsartan | 19 | $1,048 |
| Hydralazine Hcl | 64 | $997 |
| Sodium Polystyrene Sulfonate | 13 | $765 |
| Tamsulosin Hcl | 53 | $642 |
| Nifedipine ErNifedipine | 14 | $606 |
| Potassium Chloride | 35 | $464 |
| Torsemide | 24 | $439 |
| Furosemide | 126 | $393 |
| Losartan Potassium | 35 | $381 |
| Midodrine Hcl | 13 | $361 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 13 | $349 |
| Amlodipine Besylate | 64 | $298 |
| Chlorthalidone | 25 | $286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $113 | $32,38636 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $16 | $1,04819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 679 acute care providers in Georgia.
Other acute care in Watkinsville
- Dhurata GuillotWatkinsville$4K
- Darryl TurnerRinggold$21K
- Bryce CowgillCumming$16K
- Stacy CreelSavannah$15K
- Susan BeitzellAthens$13K
- Crystal KuhnCumming$12K
- Mark ClarkGainesville$10K
- Sarah WymanAtlanta$10K
- Jeffrey DillerAustell$10K
- Ayeshia PowellAtlanta$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.